Form 4 for ABUS Arbutus Biopharma Corp
Accepted 2026-02-02 00:00:00 ET · period of report 2026-02-02 · accession 0001447028-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-02 | 2026-02-02 | ABUS | Nguyen Tuan | CFO | A - Grant | $0.00 | +73.5K | 73.5K | New | $0 |
| D | 2026-02-02 | 2026-02-02 | ABUS | Nguyen Tuan | CFO | A - Grant | $0.00 | +188.4K | 188.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-02-02 | A | A | 73,500 | $0.00 | 73,500 | D | — | — | (F1) Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-02-02 | A | A | 188,400 | $0.00 | 188,400 | D | $4.39 · — to 2036-02-02 | 188,400 Common Shares | (F2) Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. (F3) This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. |